Biotech News
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
liquidia.com2026-05-06 14:58 EST
Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025